Abstract: A tissue-specific manganese based magnetic resonance imaging (MRI) agent includes the formula: wherein T includes at least one cell specific or tissue specific targeting moiety; C includes at least one pyclen based chelating agent complexed with a Mn ion, and L includes at least one optional linker that covalently links the at least one targeting moiety to the at least one chelating agent.

Abstract: A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, an aromatic group, polymer, a targeting group, or a detectable moiety; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A method of detecting drug-resistant cancer in a subject is described. The method includes contacting a tissue of the subject with an effective amount of a molecular probe, detecting the amount of the molecular probe present in the tissue, comparing the amount of molecular probe detected to a control value, and detecting drug-resistant cancer in the subject if the amount of the molecular probe present in the tissue is higher than the control value. The molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent. Methods of monitoring the treatment of drug resistant cancer are also described.

Abstract: Molecular probe compounds according to the formula P-L-I are described. P is a targeting peptide selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 117; I is an imaging agent; and L is an optional non-peptide linker that covalently links the peptide to the imaging agent, wherein the linker comprises a carboxylic acid that forms a carboxamide with an amine of the targeting peptide or a maleimide that forms a thioester bond with a cysteine residue of the targeting peptide. Methods of detecting cancer and monitoring the treatment of cancer using the molecular probes are also described.

Abstract: A nanosized complex includes a nucleic acid and a compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or a polymer, a targeting group, a detectable moiety, or a linker, or a combination thereof, and at least one of R4 and R5 includes a retinoid or retinoid derivative that targets and/or binds to an interphotoreceptor retinoid binding protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: An anticancer peptide conjugate is described that comprises the following formula: P-L-A wherein: P is a peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof in which one or more L-amino acids have been replace with a corresponding D-amino acid; A is an antitumor agent; and L is an optional linker that covalently links the peptide to the antitumor agent, and pharmaceutically acceptable salts thereof. Methods of using the anticancer peptide conjugates to treat cancer are also described.

Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: A plug connector for mating with a receptacle connector in a mating direction, includes: an insulative housing; a connecting member accommodated in the insulative housing, the connecting member having a mating portion to be mated with the receptacle connector; and a cable connected to the connecting member, wherein the insulative housing includes a first housing and a second housing integrally formed on the first housing, and the second housing is further integrally formed at a junction between the connecting member and the cable so as to fix the first housing, the cable, and the connecting member together as a whole.

Abstract: A plasmid vector comprising one or more heterologous nucleic acids or genes encoding a functional therapeutic protein configured to treat a retinal or ocular includes a human GRK1 promoter and human S/MAR enhancer to express the heterologous gene in both rod and cone photoreceptors.

Abstract: A pharmaceutical composition includes a retinylamine derivative having the following formula: where R1 is an amino acid residue, a dipeptide or a tripeptide that is linked to the retinylamine by an amide bond.

Abstract: A nanosized complex includes siRNA and a compound comprising formula (I):

Abstract: A molecular probe comprising a linear peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, and SEQ ID NO: 9; a contrast agent; and a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: A nanosized complex includes siRNA and a compound comprising formula (I):

Abstract: A compound comprising formula (I): wherein R1 is an akylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted akyl group, an akenyl group, an acyl group, an aromatic group, polymer, a targeting group, or a detectable moiety; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A PET/SPECT probe includes the following formula: P—1,—C wherein P is a EDB-FN targeting peptide, C is a PET/SPECT contrast agent; and L is an optional linker that covalently links the peptide to the contrast agent.

Abstract: A plug connector used to mate with the socket connector includes: a housing; a printed circuit board received in the housing, the circuit print board having plural soldering points; and a cable electrically connected to the soldering points of the printed circuit board, wherein the soldering points are provided with glue blocks to protect a connection between the printed circuit board and the cable.

Abstract: A plug connector includes: an insulative housing including a main body, a reinforcement projecting forward from the main body, and a pair of baffle plates; and a printed circuit board partially received in the insulative housing, the printed circuit board extending forward from the main body and beyond the reinforcement, the reinforcement wrapping on the printed circuit board, wherein a width of a front end of the printed circuit board exposed outside the main body in a horizontal direction is greater than a width of the reinforcement, and a limiting groove is formed between the baffle plate and the printed circuit board for guiding the plug connector to mate with a socket connector.

Abstract: A compound comprising formula (I): wherein R1 is an akylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted akyl group, an akenyl group, an acyl group, an aromatic group, polymer, a targeting group, or a detectable moiety; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.

Abstract: A molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent.

Abstract: An electrical connector includes: a connector unit having a mating part, the mating part defining a front mating end; a sleeve enclosing the mating part and extending forwardly beyond the front mating end to define a receiving chamber; and an outer cover enclosing the sleeve and the connector unit, wherein the sleeve has a front portion containing the receiving chamber, and the outer cover is made of a material softer than the sleeve.